| Autor: |
A. F. Yusupov, M. Kh. Karimova, S. A. Djamalova, D. K. Makhkamova, S. I. Abdullaeva, M. A. Zakirkhodjaeva, Khodjaeva Zilola, D. A. Rakhimova |
| Jazyk: |
English<br />Ukrainian |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
Journal of Ophthalmology, Iss 3, Pp 28-32 (2024) |
| Druh dokumentu: |
article |
| ISSN: |
2412-8740 |
| DOI: |
10.31288/oftalmolzh202432832 |
| Popis: |
Aim. To evaluate the short-term efficacy of using a monoclonal antibody fragment (Brolucizumab) for treating neovascular age-related macular degeneration, depending on the morphometric parameters of the retina. Methods: This study included 48 patients (60 eyes) diagnosed with neovascular age-related macular degeneration (nAMD). The observation period was 6 months. Brolucizumab was administered intravitreally at a dose of 6 mg (0.05 ml, 120 mg/ ml) once a month consistently for 3-4 months. Depending on the morphometric parameters, the retina patients were divided into three main groups. Results: A pronounced clinical and morphological response was achieved after the first injection of Brolucizumab, and positive dynamics were observed throughout the entire observation period. Conclusions: The use of the drug Brolucizumab significantly improves the visual functions of patients with neovascular AMD, as well as the morphological state of the retina in short-term follow-up, regardless of the initial morphometric characteristics of the retina, which allows not only to maintain but also to improve visual acuity and prevent blindness and visual disability in patients. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
